PPD, Inc.

PPD. (PPD) is an American contract research organization (CRO) providing comprehensive, integrated drug development, laboratory and lifecycle management services.

PPD, Inc.
TypePublic
NASDAQ: PPD
Russell 1000 Index component
IndustryContract research organizations
Pharmaceutical
Biotechnology
Founded1985
HeadquartersWilmington, North Carolina, United States
Key people
See Senior Leadership Team page of the PPD Website[1]
ProductsContract clinical research for pharmaceutical, biotechnology, medical device, academic and government organizations; services include drug development, laboratory and lifecycle management.
Revenue $4.3 Billion (2019)[2]
Number of employees
24,000+ (2020)
Websitehttps://www.ppd.com

History

PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina.

  • July 1985: Fred Eshelman, Pharm.D., founds PPD as a one-person consulting firm based in his home in Maryland.
  • 1986: Eshelman expands the company and relocates operations to Wilmington, North Carolina.
  • January 1989: The company incorporates in North Carolina.
  • January 1996: PPD issues its initial public stock offering and begins trading on the Nasdaq National Market System under the symbol PPDI.
  • October 2005: PPD's board of directors adopts an annual cash dividend policy.
  • July 2009: The company promotes Eshelman to executive chairman and names David Grange chief executive officer.[3]
  • January 2010: The company commemorates the 25th anniversary of its founding.
  • June 2010: PPD spins off its compound partnering division as a new and independent publicly traded company, Furiex Pharmaceuticals.[4]
  • May 2011: David Grange retires as chief executive officer of PPD.[5]
  • September 2011: PPD's board of directors names Raymond Hill as PPD's new chief executive officer.[6]
  • December 2011: The company is acquired by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at approximately $3.9 billion.[7]
  • May 2012: PPD's board of directors names David Simmons as chairman and CEO.[8]
  • August 2013: PPD acquires Acurian.[9]
  • December 2014: PPD announces an agreement with SNBL to form a joint venture to provide full range of clinical development services in Japan.[10]
  • May 2015: PPD expands network of U.S.-based research sites via strategic relationship with Radiant.
  • June 2016: PPD expands network of global research sites via strategic relationship with Synexus.
  • September 2016: PPD acquires Evidera.[11]
  • April 2017: Hellman & Friedman and affiliates of The Carlyle Group enter into definitive agreements to recapitalize PPD and expand the company's ownership to include two new investors, a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC Private Limited, Singapore's sovereign wealth fund.[12]
  • July 2018: PPD launches new site solution.[13]
  • July 2018: Synexus announces U.S.-based registry to power major longitudinal study on brain aging.[14]
  • February 2019: PPD inks deal with China's HLT to create data science-driven research solutions.[15]
  • May 2019: PPD's Evidera acquires RWE provider Medimix.[16]
  • September 2019: PPD's Accelerated Enrollment Solutions acquires global site business from Bioclinica.[17]
  • February 2020: PPD issues its initial public stock offering and begins trading on the Nasdaq Global Select Market under the symbol PPD.[18]

Location

PPD has headquarters in Wilmington, North Carolina. The company has more than 24,000 employees and offices in 46 countries.

References
  1. "Senior Leadership Team". Retrieved 12 June 2018.
  2. https://www.macrotrends.net/stocks/charts/PPD/ppd/revenue
  3. Wayne Faulkner (May 19, 2009). "David Grange named CEO of PPD; Eshelman named executive chairman". Wilmington StarNews.
  4. "PPD and Furiex Announce Completion of Spin-off". Retrieved 12 June 2018.
  5. Wayne Faulkner (May 20, 2011). "David Grange retires as CEO of PPD". Wilmington StarNews.
  6. "PPD appoints Raymond Hill as chief executive officer and member of the board of directors". 12 June 2018.
  7. Peter Lattman (October 3, 2011). "Buyout Firms to Buy Drug Research Company for $3.9 Billion". New York Times.
  8. William Faulkner (May 23, 2012). "PPD names new CEO". Wilmington StarNews.
  9. "PPD Acquires Acurian, Industry Leader in Patient Recruitment and Retention". August 27, 2013.
  10. John Murawski (December 24, 2014). "PPD enters into joint venture with Japanese company". The News & Observer.
  11. Ben Adams (September 8, 2016). "PPD ties off Evidera merger deal, establishes 'real world research' leader". FierceBiotech.
  12. PPD (April 26, 2017). "PPD to Recapitalize with Existing Owners and Investors".
  13. Melissa Fassbender (July 2, 2018). "PPD flips the patient enrollment model and launches new site solution".
  14. PPD (July 23, 2018). "Synexus Announces U.S.-Based Registry to Power Major Longitudinal Study on Brain Aging".
  15. Joseph Keenan (February 28, 2019). "PPD inks deal with China's HLT to create data science-driven research solutions". FierceBiotech.
  16. Melissa Fassbender (May 30, 2019). "PPD's Evidera acquires RWE provider Medimix". Outsourcing-Pharma.
  17. PPD (September 5, 2019). "PPD's Accelerated Enrollment Solutions Acquires Global Site Business from Bioclinica".
  18. Joshua Franklin (February 5, 2020). "Drug research firm PPD prices IPO at top end of target". Reuters.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.